Sitala Bio

Sitala Bio is a UK-based clinical-stage biotechnology company developing oral anti-inflammatory medicines targeting chronic, harmful inflammation that drives neurodegenerative diseases and cancer. The company's lead program is a Phase II oral inflammation blocker focused on chronic innate immune activation pathways implicated in conditions such as Parkinson's disease, Alzheimer's disease, and systemic inflammatory diseases affecting the musculoskeletal system, lungs, kidneys, gut, skin, and eyes. Sitala's scientific approach targets the dysfunction of immune cells — including microglia and astrocytes in the brain — that produce inflammatory molecules which prevent clearance of toxins such as amyloid. The company is backed by leading life sciences investors including Forbion and OrbiMed, and signed a $670M licensing deal with Fosun Pharma in 2025. Sitala Bio is headquartered in Great Shelford, Cambridge, England.